← Human Trials & Peer-Reviewed Studies
Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency.
Plain-language guide to PMID 21411551 (2011): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 152 patients.
Key Facts
- PMID
- 21411551
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Biller BM et al. (11 authors)
- DOI
- 10.1210/jc.2010-2819
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Who Took Part
According to the abstract, 152 patients were involved.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Safety was assessed from adverse events, glucose homeostasis, and antibody development.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
Changes in body composition were evaluated from DXA (dual-energy x-ray absorptiometry).
IGF-I was assessed at each study visit.
What Was Measured
PubMed files the paper under topics including Absorptiometry, Photon, Adipose Tissue, Analysis of Variance, Body Composition, Dwarfism, Pituitary, Hormone Replacement Therapy and Human Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 152 patients.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.